After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Once largely a diagnosis of exclusion, new tools and treatments are unraveling some of the mysteries surrounding heart failure with preserved ejection fraction.

A large Scandinavian study reopens the debate on beta-blockers after myocardial infarction, revealing selective benefits.

Researchers sought to assess clinical outcomes, prevalence, and 1-year outcomes associated with polypharmacy in patients with heart failure.

This case report describes a woman in her late 50s with reversible pulmonary hypertension (PH) due to scurvy, a rare vitamin ...

The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...

An FDA advisory panel unanimously agreed that Johnson & Johnson MedTech's V-Wave Ventura interatrial shunt's risks outweigh ...

A month has gone by since the last earnings report for Cytokinetics (CYTK). Shares have added about 10.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.

This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with heart failure with preserved ejection fraction (HFpEF) and ...

The FDA’s Circulatory System Devices Panel voted not to recommend approving use of an interatrial shunt to improve heart failure symptoms and prognosis.In a 0-15 vote, the committee determined risk ...